Literature DB >> 32349939

Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity.

Amedeo Lonardo1, Alessandro Mantovani2, Simonetta Lugari3, Giovanni Targher2.   

Abstract

The prevalence of nonalcoholic fatty liver disease (NAFLD) is continuing to rise in many countries, paralleling the epidemic of obesity worldwide. In the last years, the concept of metabolically healthy obesity [MHO, generally defined as obesity without metabolic syndrome (MetS)] has raised considerable scientific interest. MHO is a complex phenotype with risks intermediate between metabolically healthy individuals with normal-weight (NWMH) and patients who are obese and metabolically unhealthy (MUO, i.e. obesity with MetS). In this review we aimed to examine the association and pathophysiological link of NAFLD with MHO and MUO. Compared to NWMH individuals, patients with obesity, regardless of the presence of MetS features, are at higher risk of all-cause mortality and cardiovascular events. Moreover, MHO patients have a greater risk of NAFLD development and progression compared to NWMH individuals. However, this risk is generally lower than that of MUO patients, suggesting a stronger adverse effect of coexisting MetS disorders than obesity per se on the severity of NAFLD. Nevertheless, since MHO is a dynamic state (with a significant proportion of MHO subjects progressing to MUO over time) and NAFLD itself may predict the transition from MHO to MUO, we believe that any effort should be made to identify NAFLD in all obese individuals, although they appear to be "metabolically healthy". Future research is needed to better understand the role of NAFLD and other pathogenic factors potentially involved in the transition from MHO to MUO and to elucidate how this transition may affect the presence and severity of NAFLD.
Copyright © 2020 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Body mass index; Genetic polymorphisms; Liver fibrosis; MHO; MUO; Metabolic syndrome; NASH; Waist circumference

Mesh:

Substances:

Year:  2020        PMID: 32349939     DOI: 10.1016/j.aohep.2020.03.001

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  24 in total

1.  Children with metabolically healthy obesity have a worse metabolic profile compared to normal-weight peers: a cross-sectional study.

Authors:  Anastasios Serbis; Vasilieios Giapros; Stavroula A Paschou; Ekaterini Siomou
Journal:  Endocrine       Date:  2021-05-22       Impact factor: 3.633

2.  The gastro-jejunal anastomosis site influences dumping syndrome and weight regain in patients with obesity undergoing Laparoscopic Roux-en-Y Gastric Bypass.

Authors:  Dario Tuccinardi; Vincenzo Bruni; Rossella D'Alessio; Mikiko Watanabe; Ida Francesca Gallo; Silvia Manfrini
Journal:  Eat Weight Disord       Date:  2020-10-12       Impact factor: 4.652

Review 3.  Periodontal disease-related nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An emerging concept of oral-liver axis.

Authors:  Ryutaro Kuraji; Satoshi Sekino; Yvonne Kapila; Yukihiro Numabe
Journal:  Periodontol 2000       Date:  2021-10       Impact factor: 7.589

4.  Increasing Adiposity Is Associated With QTc Interval Prolongation and Increased Ventricular Arrhythmic Risk in the Context of Metabolic Dysfunction: Results From the UK Biobank.

Authors:  Kiran Haresh Kumar Patel; Xinyang Li; Xiao Xu; Lin Sun; Maddalena Ardissino; Prakash P Punjabi; Sanjay Purkayastha; Nicholas S Peters; James S Ware; Fu Siong Ng
Journal:  Front Cardiovasc Med       Date:  2022-06-29

Review 5.  MAFLD and CKD: An Updated Narrative Review.

Authors:  Alessandro Mantovani; Rosa Lombardi; Filippo Cattazzo; Chiara Zusi; Davide Cappelli; Andrea Dalbeni
Journal:  Int J Mol Sci       Date:  2022-06-23       Impact factor: 6.208

6.  Abdominal obesity phenotypes are associated with the risk of developing non-alcoholic fatty liver disease: insights from the general population.

Authors:  Maobin Kuang; Song Lu; Qiyang Xie; Nan Peng; Shiming He; Changhui Yu; Jiajun Qiu; Guotai Sheng; Yang Zou
Journal:  BMC Gastroenterol       Date:  2022-06-25       Impact factor: 2.847

7.  Correlation Between Anthropometric Measurements and Non-alcoholic Fatty Liver Disease in Individuals With Obesity Undergoing Bariatric Surgery: Cross-Sectional Study.

Authors:  Silênio Souza Reis; Guilherme Hoverter Callejas; Rodolfo Araújo Marques; Martinho A Gestic; Murillo P Utrini; Felipe D M Chaim; Almino C Ramos; Elinton A Chaim; Everton Cazzo
Journal:  Obes Surg       Date:  2021-05-12       Impact factor: 4.129

8.  Baseline HOMA IR and Circulating FGF21 Levels Predict NAFLD Improvement in Patients Undergoing a Low Carbohydrate Dietary Intervention for Weight Loss: A Prospective Observational Pilot Study.

Authors:  Mikiko Watanabe; Renata Risi; Elisabetta Camajani; Savina Contini; Agnese Persichetti; Dario Tuccinardi; Ilaria Ernesti; Stefania Mariani; Carla Lubrano; Alfredo Genco; Giovanni Spera; Lucio Gnessi; Sabrina Basciani
Journal:  Nutrients       Date:  2020-07-18       Impact factor: 5.717

9.  A correlation study of the relationships between nonalcoholic fatty liver disease and serum triglyceride concentration after an oral fat tolerance test.

Authors:  Xiaoyu Hou; Yunpeng Guan; Yong Tang; An Song; Jiajun Zhao; Luping Ren; Shuchun Chen; Limin Wei; Huijuan Ma; Guangyao Song
Journal:  Lipids Health Dis       Date:  2021-05-25       Impact factor: 3.876

10.  Blood SIRT1 Shows a Coherent Association with Leptin and Adiponectin in Relation to the Degree and Distribution of Adiposity: A Study in Obesity, Normal Weight and Anorexia Nervosa.

Authors:  Stefania Mariani; Maria Rosaria Di Giorgio; Erica Rossi; Rossella Tozzi; Savina Contini; Lisa Bauleo; Fiammetta Cipriani; Raffaella Toscano; Sabrina Basciani; Giuseppe Barbaro; Mikiko Watanabe; Agostino Valenti; Armando Cotugno; Carla Ancona; Carla Lubrano; Lucio Gnessi
Journal:  Nutrients       Date:  2020-11-14       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.